-
Deep neural recordings suggest the brain adapts to weight-loss drugs over time
02 Dec 2025 22:16 GMT
… to treat conditions like epilepsy or Parkinson’s disease. … patients who suffered from treatment-resistant obesity and loss- … the natural progression. Future trials may involve using the … lead to the development of more targeted medications with longer-lasting …
-
Cryo-EM Reveals How Epilepsy Drugs Engage Neuronal Protein SV2A
02 Dec 2025 12:26 GMT
… nearly all neurons, when anti-epilepsy drugs bind. They further showed … Food & Drug Administration (FDA). It is also on the … with a panel of FDA-approved and experimental anti- … role in neuronal cells. “Developing better inhibitors or modulators will …
-
<![CDATA[New Phase 2 Trial to Test TREM2-Stabilizing Agent VHB937 in Alzheimer Disease]]>
02 Dec 2025 16:21 GMT
… receiving symptomatic AD treatments such as acetylcholinesterase … brain injury or epilepsy, recent suicidal ideation … or the use of medications prohibited by the study … treatment for amyotrophic lateral sclerosis (ALS) through the phase 2 ASTRALS trial …
-
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
02 Dec 2025 16:08 GMT
… ARGUS trial for the treatment of Dravet syndrome at the 2025 American Epilepsy … an investigational product under development for the treatment of Dravet syndrome (DS … a pharmaceutical company dedicated to developing and commercializing innovative therapies for …
-
Citizen Health Joins Forces with UCB to Accelerate Drug Development across Epilepsy and Rare Diseases
02 Dec 2025 14:00 GMT
… and development. The multi-year collaboration launches with a focus on epilepsy … creation of better treatments, and engage with clinical trials earlier and more … of the KCNT1 Epilepsy Foundation, noted, “The epilepsy community needs bold partnerships …
-
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
02 Dec 2025 13:17 GMT
… RNS System is advancing the treatment of epilepsy.
Visit NeuroPace at AES … the NAUTILUS clinical trial; risks related to product development, including risks related … only. Seizure ID is under FDA review, is not approved, and …
-
Research Reveals Structural Mechanism Behind Anti-Epilepsy Therapies
02 Dec 2025 10:21 GMT
… nearly all neurons, when anti-epilepsy drugs bind. They further showed … Food & Drug Administration (FDA). It is also on the … with a panel of FDA-approved and experimental anti- … role in neuronal cells. “Developing better inhibitors or modulators will …
-
Lundbeck To Present Comprehensive New Bexicaserin Dataset In Patients With Rare Childhood-Onset Epilepsies, At American Epilepsy Society (AES) Annual Meeting
02 Dec 2025 10:09 GMT
… Medication Utilization in Participants with Developmental … and severe epilepsy syndromes are … FDA has granted Breakthrough Therapy designation for bexicaserin for the treatment … treatment of seizures associated with DEEs.
About the PACIFIC trialThe PACIFIC trial …
-
Mapping SV2A drug binding offers a path to better epilepsy treatments
02 Dec 2025 02:27 GMT
… nearly all neurons, when anti-epilepsy drugs bind. They further showed … Food & Drug Administration (FDA). It is also on the … with a panel of FDA-approved and experimental anti- … but intriguingly, not of the developmental anti-seizure drug padsevonil. While …
-
Epilepsy device-maker Epiminder lists on the ASX with $290 million market cap
01 Dec 2025 22:44 GMT
… .
The Melbourne-based company has developed a sub-scalp electroencephalogram (EEG … effective treatment, significantly improving the quality of life for people with epilepsy … his father developed the condition.
His father’s epilepsy was very poorly …
About
© 1995-2025